• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Lilium NV

    10/17/24 11:26:31 AM ET
    $LILM
    Aerospace
    Industrials
    Get the next $LILM alert in real time by email
    6-K 1 tm2426372d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

     

    For the month of October, 2024

     

    Commission File Number 001-40736

     

    Lilium N.V.

    (Translation of registrant’s name into English)

     

    Galileostraße 335

    82131 Gauting, Germany

    Telephone: +49 160 9704 6857

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F x Form 40-F ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

     

     

     

     

     

     

    CONTENTS

     

    Explanatory Note

     

    On October 17, 2024, Lilium N.V. (“Lilium”) announced that it has received indication that the budget committee of the parliament of the Federal Republic of Germany will not approve a €50 million guarantee of a contemplated €100 million convertible loan for Lilium from KfW, a German public law institution (Anstalt des öffentlichen Rechts) serving domestic and international public policy objectives of the federal government of Germany (“KfW”). Lilium is continuing discussions with the Free State of Bavaria with respect to a guarantee of at least €50 million.

      

    Incorporation by Reference

     

    The contents of this Report on Form 6-K (including the Exhibits attached hereto) are hereby incorporated by reference into the Company’s registration statements on Form F-3 filed with the U.S. Securities and Exchange Commission (“SEC”) on October 1, 2024 (File No. 333-282442), July 29, 2024 (File No. 333-281082), July 29, 2024, as amended or supplemented (File No. 333-281066), June 14, 2024 (File No. 333-280219), May 3, 2024 (File No. 333-279113), November 24, 2023 (File No. 333-275742), September 18, 2023 (File No. 333-274550), June 9, 2023 (File No. 333-272571), November 25, 2022, as amended or supplemented (File No. 333-268562), and October 3, 2022, as amended or supplemented (File Nos. 333-267718 and 333-267719), and the Company’s registration statements on Form S-8 filed with the SEC on November 18, 2021 (File No. 333-261175) and March 21, 2024 (File No. 333-278148).

     

    Forward-Looking Statements

     

    The information contained in this Report on Form 6-K contains certain forward-looking statements within the meaning of the U.S. federal securities laws, including, but not limited to, statements regarding Lilium’s consideration of various possible strategic transactions and fundraising initiatives and Lilium’s ability to obtain any additional financing. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “continue,” “could,” “expect,” “exploring,” “estimate,” “future,” “intend,” “may,” “plan,” “possible,” “potential,” “result,” “should,” “target,” “will,” “would,” and similar expressions. Forward-looking statements are predictions, projections, and other statements about future events that are based on management’s current expectations with respect to future events and are based on assumptions and are subject to risk and uncertainties that are subject to change at any time. Actual events or results may differ materially from those contained in the forward-looking statements. Factors that could cause actual future events to differ materially from the forward-looking statements in this Report on Form 6-K include the risk that appropriate government approvals for the Loan will not be obtained, and the risk that definitive documentation for the Loan will not be agreed, as well as those risks and uncertainties discussed in Lilium’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including in the section titled “Risk Factors” in Lilium’s other SEC filings, all of which are available at www.sec.gov. Forward-looking statements speak only as of the date they are made. You are cautioned not to put undue reliance on forward-looking statements, and Lilium assumes no obligation to, and does not intend to, update, or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Dated: October 17, 2024 Lilium N.V.
         
      By: /s/ Klaus Roewe
        Name: Klaus Roewe
        Title: Chief Executive Officer and Executive Director

      

     

     

    Get the next $LILM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LILM

    DatePrice TargetRatingAnalyst
    10/18/2024$2.00 → $1.00Overweight → Neutral
    Cantor Fitzgerald
    7/19/2024$2.00Overweight
    Cantor Fitzgerald
    8/1/2023$3.00Buy
    B. Riley Securities
    7/17/2023$1.20 → $3.00Hold → Buy
    Canaccord Genuity
    7/14/2023$1.20 → $3.00Hold → Buy
    Canaccord Genuity
    6/9/2023$1.20Hold
    Canaccord Genuity
    3/14/2023$1.00Neutral
    Citigroup
    12/7/2022$2.00 → $1.00Equal Weight → Underweight
    Barclays
    More analyst ratings